The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
http://www.thetimes.co.uk/tto/business/columnists/article4292892.ece "Passing test with flying colours In a dismal market, Akers Biosciences held firm. This is the £8.5 million New Jersey-based, AIM-quoted specialist in on-the-spot medical tests. Last year, Akers became only the third supplier of portable breathalysers to be awarded the NF Mark, a French kitemark, in a country where every driver on its roads must carry a working, unused, disposable breathalyser. It is also developing a fast test to diagnose lung cancer via breath. Its premium test, Heparin PF4 Rapid Assay, is on sale in the United States, where it helps to determine in minutes whether any patient being treated with the widely used blood-thinner is developing a potentially fatal allergic reaction. About 12 million patients there are given heparin every year and as many as 5 per cent develop an allergy. Yesterday, there were whispers that Akers had received its first $1 million order for the same test from China. Unlike in the US, where there is a slower laboratory test for this allergy, China has no competing test and could become the second-biggest market for the product. Akers shares, 124p two years ago, as high as 690p a little over a year ago, marked time at 215p."
Wow - remember that AKR's m/cap is just £10.8m and is virtually covered by its cash pile. And this is just an initial order, with no competition whatsoever in the Chinese market and backing from the huge Novotek.... http://www.investegate.co.uk/akers-biosciences--akr-/rns/order-to-supply-pifa-products-to-china/201412100700253100Z/ "Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the receipt of an initial purchase order (the "Order") valued at US$1,000,000 from NovoTek Therapeutics Inc. ("NovoTek") to supply PIFA Heparin PF4/Rapid Assay products in Mainland China ("China"). NovoTek, a Beijing‐based pharmaceutical and medical device business development company, holds the exclusive sales and marketing rights for the Company's PIFA Heparin/PF4 Rapid Assay products in China. The Company expects to deliver the Order by December 31, 2014. etc"
New Redchip research report just out - note the $10.8m cash compared to the £10.65m m/cap: Http://www.redchip.com/assets/reports/AKER_20141113_Research_Note.pdf Conclusion: "Target price of $11.40. We are applying a 5.0x P/S multiple to our projected FY15 revenue per share of $2.25. Our target price offers significant upside from the current price of $3.13. We believe the current entry point is very attractive, especially considering that AKER is trading just below book value (0.99x), has no debt, is generating revenue both domestically and internationally and has many pending product launches on the horizon."
Will surely be bought out in the near future
I had no worries when this one dropped 60%. . . . It just goes to show how the markets manipulate the S P. . . . The company is developing excellent products and I really think this one will climb back to £5 sooner or later
Huge potential - and this is just one of their tests: Http://www.investegate.co.uk/akers-biosciences--akr-/rns/sales-contract-for-rapid-cholesterol-test/201409091230032067R/ "9 September 2014 AKERS BIOSCIENCES ANNOUNCES $864,000 SALES CONTRACT FOR ITS RAPID RESULTS POINT OF CARE CHOLESTEROL TEST New Cholesterol Test Takes Only Three Minutes to Produce Results; Addresses a Worldwide Market Estimated at $2 Billion Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "ABI"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announced a contract valued at $864,000 for sales of its innovative Tri-Cholesterol "Check" tests in Australia, Singapore, the United Arab Emirates and Oman. The Company's products are being distributed in such regions by 36 Strategies General Trading LLC ("36S"), a Dubai-based procurement solutions company. Target customers in Australia, Singapore, the United Arab Emirates and Oman include military forces, medical associations, universities and large companies operating in the resources sector. The Company's Tri-Cholesterol "Check" is a revolutionary finger-stick blood sample technology and the only combined rapid test which provides an estimate of both Total and High Density Lipoprotein ("HDL") cholesterol levels; thereby providing an estimate of the subject's Low Density Lipoprotein ("LDL") levels. ABI's Tri-Cholesterol "Check" test carries a U.S. Food and Drug Administration ("FDA") Over-the-Counter approval; three CE marks for the European Economic Area; and a Health Canada approval. Raymond F. Akers Jr., Ph.D, Executive Chairman of Akers Biosciences, stated, "This order gives us confidence that this test could become a very important and widely used test worldwide. There are an estimated 200 million people worldwide who have abnormal cholesterol levels. Our self-administered point-of-care test for cholesterol is easy-to-use, low cost, and revolutionary in point-of-care diagnostics. We are very pleased with the sales results we have achieved in these regions in a very short time through our distribution partner in the Middle East." Revenue related to this order for Tri-Cholesterol "Check" tests (a Rapid Enzymatic Assay product) was recognized in the accounts for the six months ended June 30, 2014. "
I took the plunge and bought some of the American shares. At $3.80 or so they cost me around 220p each. I expect the pound to fall against the dollar in the future from $1.71, so there's a double positive whammy and some downside protection even if the share price falls. At that price the m/cap is £10.8m, yet at 31st March AKR had £7.5m cash and a further $1m of net receivables/payables. If the Americans latch on to the fundamentals here AKR could be a big winner imho.
Only 35.9% to go until I am even! But put another way a helluva lot better than it was!!!!
March 27th, they hired Edwin C. Hendrick to spearhead sales efforts. "In every case, Mr. Hendrick contributed to more than doubling or tripling revenues and profitability of those businesses, leading to successful sales of his past three companies to industry leaders. In his most recent position as Executive Vice President, Sales and Marketing of PLUS Diagnostics, Mr. Hendrick helped lead the company's transformation from a regional lab generating $10 million in revenues to a national leader in its field achieving more than $100 million in revenues. PLUS' growth culminated in the company's successful sale to Miraca Life Sciences in 2013. Prior to PLUS, Mr. Hendrick served as an executive with US Labs, a start-up company. He built the company's operations and sales and marketing organizations, leading a team of over 60 to achieve triple-digit growth annually, culminating in US Labs' $155 million acquisition by LabCorp. Mr. Hendrick also led sales and marketing for Ventana Medical Systems, a medical device and reagent business that was acquired by Roche Group in 2008. He launched two of the company's biggest selling product lines, contributing to revenue growth from $3 million to over $75 million. All he has to do is ramp sales to $5mil a year and we have a $7 stock
i just read. Akers Biosciences (NASDAQ: AKER) was featured this past weekend in an article that appeared in South Jersey's Courier-Post. The article gives a great overview of Akers Biosciences, stating the Company "develops, manufactures and distributes rapid, point-of-care screening and testing products. They include a portable breath alcohol detector, screens for malaria and an allergy to heparin, and a device to determine blood compatibility on a battlefield. Clients include the government of France and the U.S. military." The article goes into further detail about what's driving the Company's jump in sales and its expanding relationship with the U.S. military. Link to article below http://www.courierpostonline.com/article/20140309/BUSINESS02/303090054/-Everything-we-do-helps-people-?nclick_check=1 Clifford, share consolidation took place, 156 - 1, post placement share value at around 520 but this has retraced of late, but still holding. With what is to come, to include for the sales growth, as can be seen from the attached update, then I am happy to hold. All the very best to all here invested.
As a holder of this share some time ago I am unsure how the current price compares with that prior to the repricing. Can someone bring me up todate,please.
Any ideas?
if you want to look at the full Nasdaq application history, then this is the link http://www.nasdaq.com/markets/ipos/company/akers-biosciences-inc-668645-73185?tab=financials
looks like the listing delay is due to no5 amendment re form S-1 having been filed on the 30.12.13. Link - http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=9251672
I read a post from an investor on the ADVFN thread who said he had contacted the Akers CEO. Mr Nicolette is confident the Nasdaq IPO will take place before Xmas.
has it been excepted on NASDAQ yet
i am holding this share but at the moment it seem to have disappeared from my portfolio has anybody elses.
I also believe that if a country or US state was to make disposable breathalyzers within vehicles mandatory (like France), then Akers and Chubewokx are well placed to enter this market quickly
Im holding onto the shares for the NASDAQ launch and will reassess from there. Here is why I think the SP will rise upon NASDAQ launch - The US population is 5 times greater than the UK - likelihood of many more investors - It will be a new company floating on NASDAQ and will hopefully attract attention within the US investors media Akers have a number of products - not everything is riding on say disposable breathalysers in the French market - They have new directors on board - Knox and Moran and hopefully these guys will generate new ideas - They have partnered with CHubeworkx - think of them as a very proactive sales and marketing dept. Akers was far too scientist based in the past. - A new product has just been launched in the lucrative US diet market - Metron. This product tells you if you are burning fat or carbs during exercise. - A deal has been signed to distribute a breathalyzer in China - 9 year deal. Likely to start in earnest 2014
Haha - I've held shares in Akers since last December. If they had risen by such an amount, I would be retiring today as a multi millionaire They are preparing to float on NASDAQ as well as staying on LSE. Shares consolidated as they are looking to raise around $17 million
Did the share price really increase by 15,000%?
It's a share consolidation. Every 156 old shares have been consolidated into 1 new share. So the opening SP today should have been 536p. It's actually 527p now so it's a little bit down.
what happened here for the SP to rise so much?!
15,000% is a nice round number. :/
Good point, I might just contact investor relations and take it from there, details below. Investor Relations Vigo Communications One Berkeley Street London W1J 8DJ 020 7016 9570 www.vigocomms.com